Colgate-Palmolive Company $CL Position Lessened by Parallel Advisors LLC

Parallel Advisors LLC cut its stake in Colgate-Palmolive Company (NYSE:CL) by 7.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,916 shares of the company’s stock after selling 6,477 shares during the period. Parallel Advisors LLC’s holdings in Colgate-Palmolive were worth $6,389,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its position in Colgate-Palmolive by 4.4% in the 4th quarter. Brighton Jones LLC now owns 10,578 shares of the company’s stock valued at $962,000 after purchasing an additional 450 shares during the last quarter. Woodline Partners LP increased its stake in shares of Colgate-Palmolive by 76.3% in the first quarter. Woodline Partners LP now owns 46,361 shares of the company’s stock valued at $4,344,000 after purchasing an additional 20,062 shares during the period. Schnieders Capital Management LLC. raised its holdings in shares of Colgate-Palmolive by 2.0% during the second quarter. Schnieders Capital Management LLC. now owns 12,494 shares of the company’s stock valued at $1,136,000 after buying an additional 245 shares during the last quarter. Bryn Mawr Trust Advisors LLC boosted its position in shares of Colgate-Palmolive by 62.1% during the second quarter. Bryn Mawr Trust Advisors LLC now owns 4,322 shares of the company’s stock worth $393,000 after buying an additional 1,656 shares during the period. Finally, Vestmark Advisory Solutions Inc. bought a new position in Colgate-Palmolive in the 2nd quarter worth approximately $252,000. Institutional investors and hedge funds own 80.41% of the company’s stock.

Colgate-Palmolive Price Performance

Shares of Colgate-Palmolive stock opened at $93.55 on Monday. Colgate-Palmolive Company has a 52 week low of $74.54 and a 52 week high of $100.18. The company has a current ratio of 0.83, a quick ratio of 0.54 and a debt-to-equity ratio of 18.82. The stock has a market cap of $75.41 billion, a PE ratio of 35.71, a price-to-earnings-growth ratio of 4.22 and a beta of 0.28. The company’s 50-day moving average price is $88.98 and its two-hundred day moving average price is $83.03.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.04. Colgate-Palmolive had a net margin of 10.45% and a return on equity of 353.72%. The company had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.13 billion. During the same quarter in the previous year, the company posted $0.91 EPS. The business’s revenue was up 5.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Colgate-Palmolive Company will post 3.75 EPS for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Wednesday, January 21st were given a $0.52 dividend. The ex-dividend date was Wednesday, January 21st. This represents a $2.08 annualized dividend and a yield of 2.2%. Colgate-Palmolive’s payout ratio is 79.39%.

Analysts Set New Price Targets

Several research firms recently commented on CL. Jefferies Financial Group raised their target price on Colgate-Palmolive from $85.00 to $91.00 and gave the company a “hold” rating in a research report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft raised their price target on Colgate-Palmolive from $83.00 to $90.00 and gave the company a “hold” rating in a report on Monday, February 2nd. Argus reaffirmed a “hold” rating on shares of Colgate-Palmolive in a report on Thursday, December 11th. Royal Bank Of Canada upgraded shares of Colgate-Palmolive from a “sector perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research report on Tuesday, December 9th. Finally, Bank of America raised their target price on shares of Colgate-Palmolive from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Eleven investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Colgate-Palmolive has a consensus rating of “Moderate Buy” and an average price target of $94.75.

Insider Buying and Selling

In other news, CFO Stanley J. Sutula III sold 97,843 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $94.27, for a total transaction of $9,223,659.61. Following the completion of the sale, the chief financial officer owned 55,310 shares in the company, valued at approximately $5,214,073.70. This represents a 63.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Panagiotis Tsourapas sold 15,000 shares of Colgate-Palmolive stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $97.81, for a total value of $1,467,150.00. Following the completion of the transaction, the chief operating officer owned 10,415 shares in the company, valued at $1,018,691.15. The trade was a 59.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 184,683 shares of company stock worth $17,486,693 over the last quarter. 0.41% of the stock is currently owned by insiders.

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.